Skip to main content
Mitchell Steiner, MD, Urology, Miami, FL

MitchellS.SteinerMD

Urology Miami, FL

Surgical Oncology

Chairman, CEO, and President of Veru, Inc. (NASDAQ:VERU) 2014-present CEO, Vice Chairman of GTx (NASDAQ:GTXI) 1997-2014 Chairman and Professor, Urology, University of Tennessee, Memphis, College of Medicine

Dr. Steiner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Steiner's full profile

Already have an account?

  • Office

    48 NW 25th Street
    Suite 102
    Miami, FL 33127
    Phone+1 901-581-5872

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Urology, 1988 - 1992
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Surgery, 1986 - 1988
  • University of Tennessee Health Science Center College of Medicine
    University of Tennessee Health Science Center College of MedicineClass of 1986

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 1992 - 2026
  • MD State Medical License
    MD State Medical License 1989 - 1993

Awards, Honors, & Recognition

  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Veru to Present at the Jefferies Healthcare Conference
    Veru to Present at the Jefferies Healthcare ConferenceMay 24th, 2023
  • Veru Reports Fiscal 2023 Second Quarter Financial Results
    Veru Reports Fiscal 2023 Second Quarter Financial ResultsMay 11th, 2023
  • Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
    Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDSMay 4th, 2023
  • Join now to see all

Professional Memberships